TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05631145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MT Combined With XKSA
Description: Morita therapy (MT) comprised bed rest and light work. Xingnao Kaiqiao self-administered acupressure (XKSA) stimulates nine acupoints including Baihui, Sishenchong, Shenmen, Neiguan, Hegu, Taichong, Jianjing, Shenshu, and Yuji.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MT
Description: Morita therapy (MT) comprised bed rest and light work.
Study: NCT00158262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol short-acting or long-acting capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching propranolol short-acting or long-acting capsule
Study: NCT03798548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Bedside CBT
Description: 4 sessions of CBT including psychoeducation about TAVR and how mood can impact recovery in cardiac patients, discussion of patients' expectations and any concerns. Teaching and practice of cognitive restructuring and behavioral goal setting techniques for a healthy recovery.
Study: NCT01779063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based multimedia intervention
Description: cognitive therapy based web intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational booklet
Description: patient education booklet
Study: NCT02959918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-037
Description: SEL-037, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-037
Description: SEL-037, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic
Study: NCT04352777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: 50 - 150mg tablet BID as prescribed per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: 50 - 150mg tablet BID as prescribed per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: 500mg as prescribed per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors
Description: Letrozole, anastrozole as prescribed per standard of care
Study: NCT02096562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients use compression stockings for 10 days after surgery
Description: patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal therapy - no compression stockings
Description: the patients receive the common therapy according to S2 guidelines
Study: NCT01149031

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LOW LEVEL LASER SYSTEM
Description: LASER DIODE CLASS 3B,OMEGA XP
Study: NCT02224781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT01149031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LOW LEVEL LASER SYSTEM
Description: LASER DIODE CLASS 3B,OMEGA XP
Study: NCT04919148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat risk and pro-environment behavior message
Description: Eligible participants will be randomized to either a control condition to receive a standardized heat health warning or an intervention condition to receive a heat health warning plus figures depicting heat risk and pro-environment behavior via their preferred and accessible channel (WhatsApp, WeChat or the text message) each time when a Very Hot Weather Warning is issued by the Hong Kong Observatory.
Study: NCT01424241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.
Study: NCT02260219

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2
Description: Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2
Description: Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
Study: NCT03678194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Support System
Description: 6 weeks smartphone application with daily evaluations
Study: NCT03213392

Intervention type: DRUG
Intervention: Anesthetic Agents
Description: four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
Study: NCT03836534

Intervention type: BEHAVIORAL
Intervention: adherence to treatment of patients coming out of emergencies
Description: Phone contact of patients within 48 hours of the consultation
Study: NCT03190980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% glucose
Description: Neonates will receive 5% glucose, then heel prick wil be performed during which pain will be assessed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% glucose
Description: Neonates will receive 30% glucose, then heel prick wil be performed during which pain will be assessed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Neonates will receive sterile water, then heel prick wil be performed during which pain will be assessed
Study: NCT01150903

Intervention type: OTHER
Intervention: no intervention
Description: non-interventional study

Intervention type: OTHER
Intervention: no intervention
Description: non-interventional study
Study: NCT03173456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone/APAP
Description: Oxycodone/acetaminophen 5 mg-325 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocodone/APAP
Description: Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: codeine/APAP
Description: Codeine/acetaminophen 30 mg-300mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 ibuprofen/APAP
Description: ibuprofen/acetaminophen 400 mg-1000mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800 ibuprofen/APAP
Description: ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
Study: NCT00394888

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: MRI of the spine.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: MRI of the spine.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI of head and neck
Description: MRI of head and C-spine

Intervention type: OTHER
Group type: OTHER
Intervention: Dermatological Examination
Description: Complete dermatological examination to identify and characterize nature of dermatological anomalies

Intervention type: OTHER
Group type: OTHER
Intervention: Dermatological Examination
Description: Complete dermatological examination to identify and characterize nature of dermatological anomalies

Intervention type: OTHER
Group type: OTHER
Intervention: Dermatological Examination
Description: Complete dermatological examination to identify and characterize nature of dermatological anomalies

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac examination
Description: Complete cardiac examination

Intervention type: DEVICE
Group type: OTHER
Intervention: Abdominal ultrasound
Description: Abdominal ultrasound to detect hepatic hemangiomas
Study: NCT01651975

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Thickenup
Description: given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Thickenup Advance
Description: given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
Study: NCT04736069

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy program
Description: In the physical therapy program, 20 minutes of hot pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS; 30 to 40 Hz), 6 minutes of ultrasound (US; 1 MHz, 1 to 1.5 Watt/cm2) therapy were applied to both groups. Both of the programs were supervised by physical therapists. A combined range of motion and strengthening exercises were given to both groups to be performed two times a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy program
Description: In the physical therapy program, 20 minutes of hot pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS; 30 to 40 Hz), 6 minutes of ultrasound (US; 1 MHz, 1 to 1.5 Watt/cm2) therapy were applied to both groups. Both of the programs were supervised by physical therapists. A combined range of motion and strengthening exercises were given to both groups to be performed two times a day.
Study: NCT03025269

Intervention type: DRUG
Intervention: Ocrelizumab
Description: This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
Study: NCT04501952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDV
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match RDV
Description: Administered as an intravenous infusion
Study: NCT00418028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT04444765

Intervention type: OTHER
Intervention: Collection of clinical and biological data during renal replacement therapy sessions
Description: Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).

Intervention type: OTHER
Intervention: Collection of clinical and biological data during renal replacement therapy sessions
Description: Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).
Study: NCT03965520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise rehabilitation by near-infrared spectrometer
Description: We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise rehabilitation by near-infrared spectrometer
Description: We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
Study: NCT04428840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-measurement kiosk
Description: Use of the self-measurement kiosk, with results forwarded to the triage nurse screens
Study: NCT03130374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olfactory mucosa-derived mesenchymal stem cells
Description: Olfactory mucosa-derived mesenchymal stem cells
Study: NCT03104608

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Self Transcending Meditation
Description: Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
Study: NCT04235504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MDI
Description: Subject continues their standard Multiple Daily Injections therapy with FGM or RT-CGM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AHCL
Description: Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHCL
Description: Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment.
Study: NCT01858415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriPollar
Study: NCT01210222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV
Study: NCT01841047

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
Study: NCT01156805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
Study: NCT04832451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Relational Role Analysis
Description: Interpersonal Relational Role Analysis (IRRA) is a psychosocial group intervention that allows individuals to see the problems they experience in interpersonal relationships and interactions in the group environment and to be handled together with group members.~Similar to Yalom's interactional group therapy model, IRRA sessions comprise warm up, the stages of setting the agenda, working, evaluating, and getting feedback from observers, which are based on the 'here and now' principle. IRRA helps to safely examine the roles in which group members are stuck, in a group environment which is a small example of social life, and these roles are addressed in six steps.
Study: NCT01322087

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.~All included patients received nutritional counseling and information about the new food concept by a clinical dietician.~Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient.
Study: NCT00685360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optimized Background Regimen (OBR)
Description: Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching 50-mg tablets of delamanid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching 50-mg tablets of delamanid
Study: NCT01551446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl
Description: Oral, once daily
Study: NCT02103660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medroxyprogesterone Acetate
Description: 150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestin Contraceptive (Jadelle)
Description: 2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
Study: NCT01305707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-ECT
Description: C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.~Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PHARMACOTHERAPY
Description: Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
Study: NCT00956332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiGeneAngio
Description: Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiGeneAngio
Description: Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially